Dr. Patrick Yue is Senior Vice President of Clinical Development, Innovative Medicines.
Prior to joining Centessa, Patrick was Vice President of clinical science at Global Blood Therapeutics, where he oversaw 4 development programs, including voxelotor (Oxbryta), a treatment for sickle cell disease. Patrick has spent 12 years in the biotech/pharmaceutical industry, taking on roles of increasing responsibility at Gilead, Portola, Alexion, and Pfizer.
Prior to joining the industry, Patrick completed his medical internship and residency at Beth Israel Deaconess Medical Center and received specialty training in cardiovascular
medicine at Stanford University School of Medicine. Patrick holds a BS in biology and chemistry from the California Institute of Technology and an MD from Washington University School of Medicine.
